Evidence map›Paper›PMID 40364729›Full record

ReviewLiver international : official journal of the International Association for the Study of the Liver2025

Natural History of Idiosyncratic Drug-Induced Liver Injury and Prognostic Models.

Harshad C Devarbhavi, Raúl J Andrade

Abstract readReview
In one paragraph

Review in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Anti-Tubercular Drug-Induced Liver Injury: Current Understanding and Emerging Directions.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Harshad C DevarbhaviDepartment of Gastroenterology and Hepatology, St. John's Medical College Hospital, Bangalore, India.ORCID 0000-0002-3593-3746
Raúl J AndradeUnidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación Biomédica de Málaga. IBIMA-Plataforma BIONAND, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, (CIBERehd), Malaga, Spain.ORCID 0000-0002-1565-0757

Funding

Instituto de Salud Carlos III PI21/01248Instituto de Salud Carlos III PI24/01205
6 · The paper itself

Abstract

BACKGROUND AND

aimsDrug-induced liver injury (DILI) remains a leading cause of acute liver failure worldwide. Drugs such as isoniazid, alone or in combination with other anti-tuberculosis drugs, as well as a growing number of herbal and complementary medicines, have been implicated in most cases of acute liver failure in registry studies.

methodsThis review summarizes current knowdledge on the acute and chronic outcomes in patients with idiosyncratic DILI and discusses several of the existing prognostic models. RESULTS AND

conclusionsThe reasons why some individuals progress from DILI to end-stage liver disease are still largely unknown. However, collaborative efforts over the past few decades have provided figures on the relative incidence of drug-induced acute liver failure and allowed the development of prognostic models to predict this worse outcome at the onset of the event. The outcome of chronic DILI is less well characterised due to the lack of sufficient follow-up in cohort studies, but several phenotypes of DILI can progress to chronicity, and specific drugs such as nitrofurantoin or amiodarone are classic examples of agents leading to chronic forms of DILI. Therapy for drug-induced acute liver failure and chronic DILI is mainly supportive, although some randomised clinical trials have shown beneficial effects of N-acetylcysteine and corticosteroids.

Indexed as

Chemical and Drug Induced Liver InjuryLiver Failure, AcuteAntitubercular AgentsDisease ProgressionHumansPrognosisAntitubercular Agentschronic DILIcorticosteroidsdrug‐induced acute liver failureprognostic factors

Identifiers

PMID40364729
PMCPMC12076114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.